Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**7-Nitroindazole** is a small molecule experimental drug that acts as a selective inhibitor of neuronal nitric oxide synthase (nNOS). It is primarily used in research to study the role of nitric oxide (NO) in the brain and has demonstrated antinociceptive (pain-reducing) and neuroprotective effects in animal models. Mechanistically, it inhibits various isoforms of nitric oxide synthase, with selectivity for the neuronal form over endothelial or inducible forms. It has been investigated for its potential use in neurological diseases such as Parkinson's disease and for its effects on cerebral blood flow regulation[1][2][4][5][9]. The compound is not approved for clinical use and remains an experimental tool compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7-nitroindazole.